Ocular Therapeutix (OCUL) Tops Q2 EPS by 1c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. WCN
6. SPOT
7. BMY
8. SPY
9. FIX
10. TSCO

Go back to Ocular Therapeutix (OCUL) Tops Q2 EPS by 1c

Ocular Therapeutix™ Reports Second Quarter 2018 Financial Results and Business Update

August 7, 2018 4:00 PM EDT

DEXTENZA® NDA Resubmission Submitted and Accepted by the U.S. Food and Drug Administration

DEXTENZA Given December 28, 2018 Target PDUFA Date

BEDFORD, Mass.--(BUSINESS WIRE)-- Ocular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced financial results for the second quarter ended June 30, 2018 and provided a business update.

We are encouraged with our progress through the first half of 2018, said Antony Mattessich, President and Chief Executive Officer. The... More